Toolkits07 · In-licensing and BD evaluation
Item 07 · in-licensing and bd evaluation · KSA and GCC consumer healthcare

In-licensing and BD evaluation: one offer, one decision meeting

A 27-slide evaluation of a licensing offer or a range for sale — fit, market, price chain per SKU, forecast, returns, due-diligence list, contract points, tracker, screen and verdict — with the workbook that scores it.

Slide 3 from the In-licensing and BD evaluation example (watermarked preview)
From the worked example: slide 3 of 28. Every preview carries a watermark; the files do not.

What you will have written when you finish

  1. 1Strategic fit and the market read for the range on offer
  2. 2The price chain per SKU, from the offered transfer price to shelf
  3. 3The SKU shortlist: which of the range is viable here and which is not
  4. 4The forecast and the returns: gross margin, NPV, payback against the thresholds
  5. 5The screen and the verdict: go, conditional go with its conditions, or no
  6. 6The due-diligence list and the contract points to negotiate
  7. 7The tracker that follows the deal from offer to decision meeting

8 slides from the example

Slides 1 · 3 · 7 · 10 · 15 · 18 · 25 · 28 of 28 · click to enlarge
Slide 1
Slide 3
Slide 7
Slide 10
Slide 15
Slide 18
Slide 25
Slide 28

2 sheets from the workbook

Returns · Screen · click to enlarge
Sheet: Returns
Sheet: Screen
The problem it solves

Offers are accepted on the licensor's forecast and regretted on the shortfall clause. This evaluation builds our own number per SKU, screens it against hard gates, lists the diligence questions with owners and turns the open ones into conditions to sign.

Who it is for

Business-development lead, portfolio lead, country manager in consumer healthcare, writing for a Gulf market and presenting to a regional or global team. Also the distributor marketer who co-writes it.

Not for

Prescription brands with a medical-affairs plan, agencies pitching creative work, or anyone who needs a company's proprietary template.

Also useful with this item

Item 02 · $79
Business case and NPV workbook
built into the evaluation
Item 05 · $79
Launch plan and readiness workbook
once the deal is signed
Companion · $29
Competitor fact table and price ladder
for the set the offer competes with

Read next on pharmagrowth.co

Healthcare Private Label Marketing: How Pharmacy Chains Are Disrupting Branded Products
Strategy · 12 min read
How to Launch an OTC Product in Saudi Arabia: The Complete Playbook (2026)
Strategy · 16 min read

Every item includes

Fully editable
Text, charts, colours, logo. Move the spine into your company template in an hour; the how-to shows how.
Opens where you work
PowerPoint, Keynote, Google Slides and LibreOffice; the workbooks recalculate in Excel, Numbers, Sheets and LibreOffice. No macros, no passwords.
Instant download
The files arrive by link the moment payment clears.
Updates for twelve months
Corrections and renderer fixes to an item you bought, by email, free.
Refunds for wrong, broken or misdescribed files
Full refund or replacement within 30 days; changed your mind before downloading, 14 days.
Single-user licence, lifetime use
Any brand, any company, any market, for as long as you like. No resale, no redistribution.
Done with you
Writing this in the next eight weeks?

Three working sessions on your own document: inputs and numbers, the draft, and a review against the questions management will ask.

Ask about a session

Every example is set in one fictional world: Meridian Consumer Health, its distributor Northern Gulf Distribution Co., the scalp-care brand Clarisel and its competitors Scalvia, Sebravel, Scalpex and Trichoderm. Nahdi, Al-Dawaa and United are real Saudi pharmacy chains used as market fixtures with invented figures, as are the marketplaces, the quick-commerce apps and the discounter named in item 08. You see every box filled, every chart populated and every number reconciled, without a real company's data.